about
Contemporary concepts in studies on cyclic AMP and its role in the inflammatory reactionMethods of estimation of IC50 and SC50 parameters for indirect response models from single dose data.Approaches to pharmacokinetic/ pharmacodynamic modeling during pregnancy.Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice.Diversity of mechanism-based pharmacodynamic models.Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study.Activity and Safety of Inhaled Itraconazole Nanosuspension in a Model Pulmonary Aspergillus fumigatus Infection in Inoculated Young Quails.CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersCaffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in micePhysiologically based modeling of lisofylline pharmacokinetics following intravenous administration in miceEffect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in micePK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response.PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research.Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.Antidepressant-like activity of sildenafil following acute and subchronic treatment in the forced swim test in mice: effects of restraint stress and monoamine depletion.The influence of caffeine on the activity of moclobemide, venlafaxine, bupropion and milnacipran in the forced swim test in mice.Pharmacokinetics and tissue distribution of the new non-imidazole histamine H3 receptor antagonist 1-[3-(4-tert-butylphenoxy) propyl]piperidine in rats.High-Energy Ball Milling as Green Process To Vitrify Tadalafil and Improve Bioavailability.Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice.A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension.Pharmacokinetic-pharmacodynamic modeling of methylxanthine derivatives in mice challenged with high-dose lipopolysaccharide.Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.Pharmacokinetic interaction between verapamil and methylxanthine derivatives in mice.Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression.Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the activity of two atypical antidepressant drugs, mianserin and tianeptine, in the forced swim test in mice.Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections.Pretreatment with R(+)-verapamil significantly reduces mortality and cytokine expression in murine model of septic shock.Influence of sildenafil on the antidepressant activity of bupropion and venlafaxine in the forced swim test in mice.Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression.In vitro and in vivo behavior of ground tadalafil hot-melt extrudates: How the carrier material can effectively assure rapid or controlled drug release.Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties.Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice.Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method.Enantioselective analysis of ibuprofen enantiomers in mice plasma and tissues by high-performance liquid chromatography with fluorescence detection: Application to a pharmacokinetic study.Sildenafil, a phosphodiesterase type 5 inhibitor, reduces antidepressant-like activity of paroxetine in the forced swim test in mice.Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine.Interconversion and tissue distribution of pentoxifylline and lisofylline in mice.Sevoflurane increases fade of neuromuscular response to TOF stimulation following rocuronium administration in children. A PK/PD analysis.Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children.
P50
Q26799951-18968EA9-F251-49EF-A926-3550F8C205BEQ30805798-E9D9DB7C-6020-4E56-9BFF-39DBA708847CQ34308683-BF70F67A-B8DB-4CB7-895D-3AC11BD90624Q34507065-987A2947-C914-41C9-9752-09E0918B4201Q35107049-D6510014-9ABF-4616-BF48-BBB5C738E660Q35599754-905A4BAA-53C9-49CA-A78B-4C5C5A8F643DQ35837664-A3EC97CF-50CA-4F64-A535-3376335AABEBQ36164941-EEBE8CBB-69B2-4D23-9EEB-99229B746258Q36471008-738D8A4B-9C45-4D6A-9028-7FFC895094F6Q37112481-1989461D-91BC-4EBB-8ABA-EEB171981721Q37693900-3C028653-3B6A-4479-BB72-372031504F21Q38653998-4E8D8FDE-7501-4D68-9172-AC405F82CFA2Q39091573-9696306B-0F62-4B42-AEB5-7118E08AFFD3Q39143939-A120F489-92BD-4A29-A8DA-F017A56D4DC4Q40709156-C71C588A-A1FF-4645-B93E-27A64DA3ADDEQ40775206-4CD836F7-9A7F-441E-8F4F-2B0E63A32DF5Q41079438-3170611E-CF00-435C-A9D6-EF6FD730083CQ41598258-9A152115-070A-42EF-B6CE-C96C6B4514F0Q42015236-8668E0D0-76F2-4B41-BA6A-F1396AC0EE0EQ42177042-AD251B78-DBE8-4AC4-A700-774CEC254137Q42256834-37D0DECE-9E92-4499-97BC-E67B904FBCF0Q43100789-4671F530-EE10-4902-9E53-3544C359B79BQ43136378-B56ABBF7-464C-42BB-9C1B-F67CF69DC7DBQ43143161-0D7B58C7-5B21-44B0-B109-5287E1D00472Q43567778-9DDB3729-5A24-4BD1-87CD-CC63AEF52D57Q44014551-B8B30B9C-C411-4457-9D75-2D5F4617C9C2Q45271008-557D92D2-B226-4525-A394-09DCB68D991EQ46085832-7682A7F0-FA02-4F8E-8668-A677D15B4416Q47197710-667C8EAE-1ACD-4A72-A6C1-090FA871CCFEQ47437307-2741A25E-68E9-42D1-AD5C-FF2BF65E8651Q47824013-DD9C1C29-F16B-4B9A-86DB-F5EF8DD6F48DQ47851923-2460077D-597D-4409-97C1-19C8F12029AEQ48050098-339D75DD-7D34-4BFA-8F3A-22ABC3216815Q48137347-D3BB8261-44FB-404A-9E6B-0B72BAECBA70Q48176246-2D879DE8-4A2D-453C-93EA-AD801E08DF68Q48254496-69EA854D-4B16-4ED6-B1C4-F9818AC23DABQ48378288-8FCD1821-B869-4C18-93E9-ED96A5B823CAQ48524476-44FECAEC-C7FC-433C-A276-269C1C3F1D23Q48591377-3FED4D09-E88F-404B-A335-A3438057532FQ48676307-327421D1-4FD0-4FAE-8F16-B5BDE907739E
P50
description
Polish researcher
@en
Pools onderzoekster
@nl
polska naukowiec
@pl
taighdeoir Polannach
@ga
name
Elżbieta Wyska
@ast
Elżbieta Wyska
@ca
Elżbieta Wyska
@cs
Elżbieta Wyska
@de
Elżbieta Wyska
@en
Elżbieta Wyska
@es
Elżbieta Wyska
@fr
Elżbieta Wyska
@ga
Elżbieta Wyska
@gl
Elżbieta Wyska
@hr
type
label
Elżbieta Wyska
@ast
Elżbieta Wyska
@ca
Elżbieta Wyska
@cs
Elżbieta Wyska
@de
Elżbieta Wyska
@en
Elżbieta Wyska
@es
Elżbieta Wyska
@fr
Elżbieta Wyska
@ga
Elżbieta Wyska
@gl
Elżbieta Wyska
@hr
prefLabel
Elżbieta Wyska
@ast
Elżbieta Wyska
@ca
Elżbieta Wyska
@cs
Elżbieta Wyska
@de
Elżbieta Wyska
@en
Elżbieta Wyska
@es
Elżbieta Wyska
@fr
Elżbieta Wyska
@ga
Elżbieta Wyska
@gl
Elżbieta Wyska
@hr
P214
P106
P1153
6603407641
P1412
P1559
Elżbieta Wyska
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-4798-0574
P735
P7859
viaf-250621287